Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 1 examiners • 0 of 2 (0%) have an AI response strategy ready
Cantai Therapeutics Inc. currently has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. Both actions are assigned to 1 distinct examiner and are situated within 1 distinct art unit. This concentration suggests that the pending matters are likely related or fall under the same specific technical sub-category. The focus on 1 examiner and 1 art unit within the Biotechnology & Pharmaceuticals field allows for a highly unified approach to prosecution.
DAHLE, CHUN WU is the busiest examiner, managing 2 pending office actions. Since DAHLE, CHUN WU is the only examiner involved, the applicant can develop a consistent strategy across both pending cases. This arrangement simplifies the administrative burden, as the applicant only needs to manage 1 examiner relationship and 1 set of art unit standards. The outcome of 1 pending action is likely to be indicative of the outcome for the other, given that the same individual is reviewing both matters. Practitioners can focus their efforts on understanding the specific examination style and history of DAHLE, CHUN WU to navigate the current portfolio effectively.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DAHLE, CHUN WU | 2 | 50.2% | +51.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19238328 | ENGINEERED BISPECIFIC MOLECULES AND METHODS OF USE | DAHLE, CHUN WU | 51d overdue |
| 19238329 | ENGINEERED BISPECIFIC MOLECULES AND METHODS OF USE | DAHLE, CHUN WU | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19238328 | ENGINEERED BISPECIFIC MOLECULES AND METHODS OF USE | DAHLE, CHUN WU | 51d overdue |
| 19238329 | ENGINEERED BISPECIFIC MOLECULES AND METHODS OF USE | DAHLE, CHUN WU | — |
| Art Unit | Apps |
|---|---|
| 1641 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19238329 | ENGINEERED BISPECIFIC MOLECULES AND METHODS OF USE | DAHLE, CHUN WU | 1641 | §103§112 | Non-Final OA | — | Pending | Jun 13, 2025 |
| 19238328 | ENGINEERED BISPECIFIC MOLECULES AND METHODS OF USE | DAHLE, CHUN WU | 1641 | §103§112 | Non-Final OA | 51d overdue | Pending | Jun 13, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial